# The Rebate Model Shift: Impact on 340B Providers

**7** 340B Eligible Organizations

would advance

# \$700M

in one year under the Rebate Pilot



#### **6 Month Sample Overview**

(Data from Jan 1 – Jun 30, 2025)

- 17 Provider Organizations
- 81 Covered Entities
- 160,675 Prescription Claims
- 908 Contract Pharmacy Relationships

## **Spend Comparison**

340B Discount Spend \$81.8M

vs.

Rebate Model (WAC Spend) \$430.5M

Minimum

10 Days
Reimbursement Delay



+\$348.7M

Additional Outlay Required

## The Craneware Group is Advocating for

- ✓ Operational continuity & cash flow
- ✓ Minimized administrative burden
- ✓ Transparent, fair rebate resolution
- ✓ Secure, streamlined data use



Funds that would support cancer care, maternal health, and emergency services are instead tied up while providers wait ten or more days for rebates.

### craneware group

#### About The Craneware Group

The Craneware Group, the leader in healthcare financial and operational transformation, delivers innovative solutions that drive measurable impact. Our Trisus® cloud ecosystem integrates data, value cycle intelligence, and analytics to optimize financial sustainability and strategic growth. As a trusted Microsoft partner, we provide future-ready technologies, including the Best in KLAS Trisus Chargemaster. Recognized for our industry excellence, we empower organizations with award-winning solutions to achieve financial success while improving outcomes for the communities they serve.